Lead Product(s): Daptomycin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Sandoz Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition March 23, 2020
Sandoz acquires the distribution rights in the United States for daptomycin 500mg injection and fosaprepitant 150mg for injection from BE Pharmaceuticals AG.